Antonia S, et al. Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC. IASLC 2018, abstract PL02.01.
Betere overleving na stoppen met roken bij NSCLC-diagnose
mrt 2024 | Longoncologie